glp-1 stock market How to Invest in Drugs: Stocks and Funds to Watch GLP-1 Receptor Agonist Market Size,

In a Phase 2 obesity trial of retatrutide published in the New England Journal of Medicine in 2023, nausea, diarrhea, vomiting and constipation were cited as the most common adverse events, with higher doses associated with more severe problems

135,136 It is considered a significant breakthrough in diabetes treatment and is also being studied for the treatment of obesity due to its significant weight loss effects

In early Phase 2 trials, participants lost up to approximately 24% of their body weight over 48 weeks at higher doses

This effect can be particularly beneficial for patients who seek to manage their weight effectively and sustainably